September 1, 2023 — Affibody Spotlights PET Agent Findings Unveiled at EANM 2023
Affibody is drawing attention to data presented during the European Association of Nuclear Medicine (EANM) 2023 annual conference, shedding light on the potential of their PET imaging agent, ABY-025, in predicting therapeutic responses.
The phase II study, conducted at Sweden’s Uppsala University Hospital, is part of Affibody’s radiopharmaceutical program. It sought to determine whether Ga-68 ABY-025, used for noninvasive quantification of HER2 status in solid tumors through PET/CT scans, could effectively monitor early treatment responses in both primary breast cancer cases designated for neoadjuvant chemotherapy and cases of metastatic breast cancer.
Dr. Jens Sörensen from Uppsala University is set to present the data on September 12th, under the title “HER2-targeting [Ga-68] ABY-025 PET Predicts Early Metabolic Response in Metastatic Breast Cancer.”
Furthermore, during the same session, a second presentation pertaining to Affibody’s radiopharmaceutical program will be delivered, titled “HER2-specific Affibody Molecule [Tc-99m] ZHER2:41071: phase I clinical trial.” This presentation will highlight the outcomes of a phase I study exploring the use of a single-photon emission computed tomography (SPECT) imaging agent to assess HER2 uptake.
Relatedd Topics:
